Fibroblast growth factor 21 (FGF21): diagnostic, prognostic and therapeutic aspects in heart failure. A review
- Authors: Alieva A.M.1, Teplova N.V.1, Reznik E.V.1, Baykova I.E.1, Khadzhieva N.K.2, Voronkova K.V.1, Kovtiukh I.V.1, Valiev R.K.3, Kotikova I.A.1, Nikitin I.G.1
-
Affiliations:
- Pirogov Russian National Research Medical University
- MedEstet Genetics and DNA Clinic
- Loginov Moscow Clinical Scientific Center
- Issue: Vol 26, No 1 (2024): Cardiology and Nephrology
- Pages: 40-44
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/256819
- DOI: https://doi.org/10.26442/20751753.2024.1.202593
- ID: 256819
Cite item
Full Text
Abstract
Chronic heart failure (CHF) is a global medical, social and economic problem. Currently, the search and study of new biomarkers that can provide early diagnosis of CHF, serve as a laboratory tool for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria are ongoing. Scientists' interest is focused, in particular, on studying the role of fibroblast growth factor 21 (FGF21) in CHF. There is increasing evidence highlighting the value of FGF21 as a new marker for the diagnosis and assessment of prognosis in patients with CHF. The role of FGF21 in CHF is very interesting due to its cardioprotective aspects. Final confirmation of the diagnostic, prognostic and therapeutic roles of FGF21 will come from future studies.
Full Text
##article.viewOnOriginalSite##About the authors
Amina M. Alieva
Pirogov Russian National Research Medical University
Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
Cand. Sci. (Med.)
Russian Federation, MoscowNatalia V. Teplova
Pirogov Russian National Research Medical University
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-7181-4680
D. Sci. (Med.), Prof.
Russian Federation, MoscowElena V. Reznik
Pirogov Russian National Research Medical University
Email: elenaresnik@gmail.com
ORCID iD: 0000-0001-7479-418X
D. Sci. (Med.), Prof.
Russian Federation, MoscowIrina E. Baykova
Pirogov Russian National Research Medical University
Email: 1498553@mail.ru
ORCID iD: 0000-0003-0886-6290
Cand. Sci. (Med.)
Russian Federation, MoscowNyurzhanna Kh. Khadzhieva
MedEstet Genetics and DNA Clinic
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-5520-281X
Cand. Sci. (Med.)
Russian Federation, MoscowKira V. Voronkova
Pirogov Russian National Research Medical University
Email: kiravoronkova@yandex.ru
ORCID iD: 0000-0003-1111-6378
D. Sci. (Med.)
Russian Federation, MoscowIrina V. Kovtiukh
Pirogov Russian National Research Medical University
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-9176-1889
Аssistant
Russian Federation, MoscowRamiz K. Valiev
Loginov Moscow Clinical Scientific Center
Email: radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
Cand. Sci. (Med.)
Russian Federation, MoscowIrina A. Kotikova
Pirogov Russian National Research Medical University
Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
Student
Russian Federation, MoscowIgor G. Nikitin
Pirogov Russian National Research Medical University
Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- Lee J, Oh O, Park DI, et al. Scoping review of measures of comorbidities in heart failure. J Cardiovasc Nurs. 2024;39(1):5-17. doi: 10.1097/JCN.0000000000001016
- Doherty DJ, Docherty KF, Gardner RS. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure. Heart. 2024;110(7):466-75. doi: 10.1136/heartjnl-2022-322164
- Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134-9 [Kalyuzhin VV, Teplyakov AT, Chernogoryuk GE, et al. Chronic heart failure: syndrome or disease? Bulletin of Siberian Medicine. 2020;19(1):134-9 (in Russian)]. doi: 10.20538/1682-0363-2020-1-134-139
- Kretzschmar T, Westphal J, Neugebauer S, et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17(1):e010813. doi: 10.1161/CIRCHEARTFAILURE.123.010813
- Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды – маркеры и факторы прогноза при хронической сердечной недостаточности. Креативная кардиология. 2007;1-2:126-36 [Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides: markers and prognostic factors in chronic heart failure. Creative Cardiology. 2007;1-2:126-36 (in Russian)].
- Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2007;47(1):45-51 [Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. The Russian Journal of Cardiology & Cardiovascular Surgery. 2007;47(1):45-51 (in Russian)].
- Goutam RS, Kumar V, Lee U, Kim J. Exploring the structural and functional diversity among FGF signals: A comparative study of human, mouse, and xenopus FGF ligands in embryonic development and cancer pathogenesis. Int J Mol Sci. 2023;24(8):7556. doi: 10.3390/ijms24087556
- Yan J, Nie Y, Cao J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8:655575. doi: 10.3389/fcvm.2021.655575
- Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022;8(1):19-25. doi: 10.1016/j.cdtm.2021.08.005
- Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci. 2021;58(5):311-28. doi: 10.1080/10408363.2020.1864278
- Falamarzi K, Malekpour M, Tafti MF, et al. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375. doi: 10.3389/fmed.2022.967375
- Алиева А.М., Байкова И.Е., Резник Е.В., и др. Фактор роста фибробластов 21-новый инструмент в многокомпонентной оценке сердечно-сосудистых заболеваний. Российский медицинский журнал. 2022;28(1):75-88 [Alieva AM, Baikova IE, Reznik EV, et al. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Russian Medicine. 2022;28(1):75-88 (in Russian)]. doi: 10.17816/medjrf108900
- Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne). 2023;14:1150222. doi: 10.3389/fendo.2023.1150222
- Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. doi: 10.1172/JCI23606
- Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37. doi: 10.3389/fphys.2019.00037
- Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790-7. doi: 10.1016/j.cmet.2013.03.019
- Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. doi: 10.2337/db05-1435
- Rosales-Soto G, Diaz-Vegas A, Casas M, et al. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020:JME-19-0210.R2. doi: 10.1530/JME-19-0210
- Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev. 2023;28(1):261-72. doi: 10.1007/s10741-022-10268-0
- Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-24. doi: 10.2337/db09-1878
- Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. doi: 10.1016/j.cmet.2014.07.012
- Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781-9. doi: 10.2337/db10-0193
- Geng L, Liao B, Jin L, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26(10):2738-52.e4. doi: 10.1016/j.celrep.2019.02.014
- Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. doi: 10.1038/ncomms3019
- Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31. doi: 10.1093/cvr/cvu263
- Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459(1):124-30. doi: 10.1016/j.bbrc.2015.02.081
- Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol (Lausanne). 2015;6:133. doi: 10.3389/fendo.2015.00133
- Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. doi: 10.1155/2020/1452696
- Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice. Cell Metab. 2018;27(6):1323-37.e5. doi: 10.1016/j.cmet.2018.04.002
- Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28. doi: 10.1007/s11906-017-0730-5
- Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. doi: 10.3389/fendo.2023.1220426
- Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301-9. doi: 10.1016/j.intimp.2018.01.048
- Furukawa N, Koitabashi N, Matsui H, et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. Heart Vessels. 2021;36(1):136-46. doi: 10.1007/s00380-020-01711-z
- Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. doi: 10.1038/srep33953
- Fan L, Gu L, Yao Y, Ma G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Methods Med. 2022;2022:7138776. doi: 10.1155/2022/7138776
- Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. doi: 10.1161/CIRCHEARTFAILURE.121.008910
- Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagnostics (Basel). 2021;11(9):1577. doi: 10.3390/diagnostics11091577
- Gu L, Jiang W, Zheng R, et al. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology. 2021;146(1):27-33. doi: 10.1159/000509239
- Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. Peer J. 2023;11:e14855. doi: 10.7717/peerj.14855
- Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1108234. doi: 10.3389/fendo.2023.1108234